Abstract Aims/hypothesis: Recent studies have shown that the inflammatory process is involved in the pathogenesis of diabetic nephropathy. Fourteen-membered ring macrolides, including erythromycin, have anti-inflammatory, as well as antibacterial effects. The aim of this study was to investigate the renoprotective effects of erythromycin in streptozotocin (STZ)-induced diabetic rats. Methods: STZinduced diabetic rats were treated orally with erythromycin (5 mg/kg body weight) or vehicle every day for 8 weeks.
Introduction
Diabetic nephropathy is a leading cause of end-stage renal disease (ESRD) in many developed countries. It is well known that modulation of the renin-angiotensin system by ACE inhibitors (ACEI) and angiotensin II type 1 receptor antagonists (ARB) is effective in the treatment of diabetic nephropathy [1, 2] . Although ACEI and ARB play central roles in the therapy for diabetic nephropathy, additional new strategies are required because these drugs cannot completely prevent disease progression.
Several mechanisms contribute to the development of diabetic nephropathy. Glomerular hyperfiltration, which is noted in the early stage of diabetic nephropathy, causes glomerular injury in type 1 and type 2 diabetes [3] . Hyperglycaemia accelerates the accumulation of diacylglycerol and activates protein kinase C, resulting in overexpression of the genes encoding TGFB (also known as TGF-β) and extracellular matrix components in the mesangial cells and glomeruli [4] . Advanced glycation end-products stimulate mesangial cells and increase the production of extracellular matrix proteins such as type IV collagen [5, 6] .
In addition to the pathways described above, recent studies have shown the involvement of inflammatory mechanisms in the pathogenesis of diabetic nephropathy. Furuta et al. [7] reported that macrophages infiltrate into renal tissues during the moderate stage of diabetic glomerulo-sclerosis, suggesting that macrophages contribute to irreversible structural damage in type 2 diabetic patients. It has also been reported that glomerular and interstitial injury is associated with macrophage infiltration in both experimental type 1 and type 2 diabetes [8, 9] . Leucocyte infiltration into inflammatory sites and atherosclerotic lesions is mediated by cell adhesion molecules and chemokines such as chemokine (C-C motif) ligand 2 (CCL2) (also known as monocyte chemoattractant protein-1). We have recently demonstrated in a series of studies [10] [11] [12] that intercellular adhesion molecule-1 (ICAM-1) is upregulated and mediates macrophage infiltration in diabetic kidney tissues. We have also shown that ICAM-1 deficiency protects against renal injuries after induction of diabetes using ICAM-1 knockout mice [13] . Our recent studies strongly suggest that inflammatory mechanisms are involved in the pathogenesis of diabetic nephropathy and that ICAM-1 plays a central role in macrophage infiltration into diabetic kidney.
Fourteen-membered ring macrolides such as erythromycin have anti-inflammatory effects independent of their antibacterial effect in the fields of respiratory medicine and otolaryngology. Low-dose and long-term therapy with erythromycin, which reduces ICAM-1 expression in the airway epithelial cells and inhibits rhinovirus infection, is effective for chronic obstructive pulmonary disease, diffuse panbronchiolitis and chronic sinusitis [14] [15] [16] [17] . It has also been reported that macrolides reduce the progression of bleomycin-induced lung injury in mice by inhibiting the induction of adhesion molecules, and neutrophil and macrophage migration into the airspace [18, 19] .
The aim of this study was to investigate whether erythromycin, through its anti-inflammatory effect, protects against diabetic nephropathy in a model of streptozotocin (STZ)-induced diabetic rats.
Materials and methods

Animal model and experimental design
Protocol 1 Four-week-old Sprague-Dawley rats (CLER Japan, Tokyo, Japan) (mean body weight±SEM: 99.0± 2.0 g) were divided into the following four groups: (1) non-diabetic group (ND; n=6); (2) non-diabetic group treated with erythromycin (ND+EM; n=6); (3) STZ-induced diabetic group (DM; n=6); and (4) diabetic group treated with erythromycin (DM+EM; n=6). At the age of 5 weeks, rats chosen for the DM and DM+EM groups received intravenous injections of STZ (Sigma Chemical, St Louis, MO, USA) at 65 mg/kg body weight in citrate buffer (pH 4.5). Rats in the ND group received citrate buffer injections only. Starting from 7 days before the STZ injections, erythromycin (5 mg/kg body weight) in 4.2% ethanol was orally administrated with a conductor to rats in the ND+EM and DM+EM groups. This was done daily. Rats in the DM group received vehicle, administered in the same way.
All rats had free access to a standard diet and tap water. All procedures were performed according to the Guidelines for Animal Experimentation at the Okayama University Medical School, Japanese Government Animal Protection and Management Law (No.105), and Japanese Government Notification on Feeding and Safekeeping of Animals (No.6). Eight weeks after induction of diabetes in the DM and DM+EM groups, all rats were killed under ether anaesthesia and the kidneys were removed and weighed. Erythromycin base was donated by Dainippon Pharmaceutical (Osaka, Japan).
Protocol 2 An additional experiment was performed to assess glomerular haemodynamics at the early stage of diabetes. Diabetes was induced in the rats of the four groups as described in Protocol 1. Two weeks after induction of diabetes, all rats in this experiment were killed, and we measured creatinine clearance (Ccr) and kidney weight.
Metabolic data and functional measurements
Systolic blood pressure was measured by the tail-cuff method (Softron, Tokyo, Japan) at 4 and 8 weeks after induction of diabetes. HbA 1 c, blood glucose and serum creatinine were assessed at 4 and 8 weeks after induction of diabetes. Urine samples were collected over a 24-h period in individual metabolic cages at 2, 4 and 8 weeks after induction of diabetes. HbA 1 c, was measured by the HPLC method. Serum and urine creatinine were measured using enzymatic methods. The urinary albumin concentration in a 24-h urine collection was measured by nephelometry using anti-rat albumin antibody (ICN Pharmaceuticals, Aurora, OH, USA). Creatinine clearance (ml min
) was calculated as [urinary creatinine volume/serum creatinine]/body weight. In Protocol 2, the above data were assessed at 2 weeks after induction of diabetes.
Assessment of kidney morphology by light microscopy
Renal tissues were fixed in 10% formalin and embedded in paraffin in routine fashion. Paraffin sections were cut at 4-μm thickness and stained with periodic acid-methenamine. To evaluate the glomerular size and mesangial matrix area, 20 randomly selected glomeruli per animal were examined. The glomerular tuft area was measured by manually tracing the glomerular tuft using PhotoShop version 6 (Adobe systems, San Jose, CA, USA) and analysed by Scion Image analysis software (Scion, Frederick, MD, USA). The mesangial matrix area was defined as the area positive for periodic acid-methenamine within the tuft area. The mesangial matrix index represented the ratio of mesangial matrix area to glomerular tuft area, as described previously [13] .
Immunoperoxidase staining for macrophages Infiltration of macrophages into the glomeruli was evaluated by immunoperoxidase staining using the ABC kit (Vector Laboratories, Burlingame, CA, USA) as described previously [9] . Briefly, frozen sections were cut at 4-μm thickness using a cryostat. Sections were incubated with a mouse monoclonal antibody against rat monocyte/macrophage (ED1) for 12 h at 4°C. The sections were then incubated with biotin-labelled goat anti-mouse IgG for 30 min at room temperature. Peroxidase activity was identified by reaction with 3,3′-diaminobenzidine. Mayer's haematoxylin was added as a counterstain. The average number of ED1-positive cells per glomerulus was calculated by counting the cells in 30 glomeruli per animal.
Immunofluorescence staining for ICAM-1 and type IV collagen
To evaluate the production of ICAM-1 and type IV collagen, immunofluorescence staining was performed as described previously [12, 20] . The frozen sections (4 μm) were stained with a monoclonal antibody against rat ICAM-1 (CD54) for 12 h at 4°C. The sections were then incubated with fluorescein-isothiocyanate-conjugated goat anti-mouse IgG for 30 min at room temperature. To characterise the change in mesangial matrix protein, rabbit anti-type IV collagen antibody was used for the primary reactions followed by a second reaction with fluoresceinisothiocyanate-conjugated goat anti-rabbit IgG (H+L).
Micrographic fluorescence photos were obtained using a laser-scanning confocal microscope (LSM-510; Carl Zeiss, Jena, Germany). The immunofluorescence intensity of ICAM-1 and type IV collagen was quantified by the modified method, as described previously [20] . In brief, colour images were obtained as TIFF target image files from the LSM-510. The brightness of each image file was uniformly enhanced by Photoshop (Adobe), followed by analysis using image analysis software (Scion). TIFF target image files were inverted and opened in grey scale mode. The ICAM-1 index and type IV collagen index were calculated using the formula: positive area mean density × positive area (μm 2 )/glomerular total area (μm 2 ), where the staining density is indicated by a number from 0 to 256 in grey scale. We evaluated 30 glomeruli per animal.
Quantitative analysis of Tgfb1 and Ccl2 mRNA by real-time RT-PCR Total RNA was extracted from each specimen of renal cortex using the RNeasy kit (Qiagen, Valencia, CA, USA). Single-strand complementary DNA was synthesised from the extracted RNA using a reverse transcription-PCR kit (Perkin Elmer, Foster City, CA, USA) according to the manufacturer's instructions. To evaluate mRNA expression of Tgfb1, Ccl2 and Actb (which encodes β-actin) in renal cortex, quantitative real-time RT-PCR was performed using a Light Cycler and LightCycler-FastStart SYBR Green 1 (Roche Diagnostics, Tokyo, Japan). After the addition of primers (final concentration: 0.3 μmol/l), MgCl 2 (3 mmol/l) and template DNA to the master mix, 45 cycles of denaturation (95°C for 10 s), annealing (60°C for 15 s) and extension (72°C for 10 s) were performed. To determine the specificity of each primer set, melting curve analysis was performed after the completion of PCR amplification. Accumulated levels of fluorescence were analysed by the fit-point method after melting curve analysis. The mRNA level of Tgfb1 and Ccl2 was normalised with a house-keeping gene (Actb) in each sample by calculating the relative expression ratio. For amplification of the complementary DNA, the following oligonucleotide primers specific for rat Tgfb1 (GenBank; X52498), Ccl2 (GenBank; M57441) and Actb (GenBank; NM_031144) were used: Tgfb1, sense 5′-GCAACAACGCAATCTAT GAC-3′, antisense 5′-CCTGTATTCCGTCTCCTT-3′; Ccl2, sense 5′-TCGGCTGGAGAACTACAAG -3′, antisense 5′-C TGAAGTCCTTAGGGTTGATG-3′; Actb, sense 5′-CCTG TATGCCTCTGGTCGTA-3′, antisense 5′-CCATCTCTT GCTCGAAGTCT-3′ (Nihon Gene Research Labs, Sendai, Japan). Each experiment was performed twice.
Electrophoretic mobility shift assay
Tissue extracts and electrophoretic mobility shift assay for the transcription factor nuclear factor-κB (NF-κB) were performed as previously described [20] . In brief, frozen renal cortex was minced and suspended in 1 ml of TBS buffer (25 For the electrophoretic mobility shift assay, the following oligonucleotide containing an NF-κB binding site was used: 5′-AGTTGAGGGGACTTTCCCAGGC-3′ (Santa Cruz Biotechnology, Santa Cruz, CA, USA). A mutant motif with G to C substitution (5′-AGTTGAGGCGAC TTTCCCAGGC-3′; Santa Cruz Biotechnology) served as a control. The consensus oligonucleotide was labelled with [γ- , untreated diabetic rats (DM group; filled circles) and diabetic rats treated with erythromycin (DM+EM group; filled squares). Although urinary albumin excretion in the DM group progressively increased compared with the ND and ND+EM groups, it was significantly reduced by treatment with erythromycin at week 8. Data are means±SEM of six rats in each group. *p<0.05 vs ND group and ND+EM group; **p<0.01 vs DM+EM group; † p<0.001 vs ND group and ND+EM group Fig. 2 Periodic acid-methenamine staining in glomeruli from a nondiabetic rat (a), a non-diabetic rat with erythromycin (b), an untreated diabetic rat (c) and an erythromycin-treated diabetic rat (d) (magnification ×400). Glomerular size (tuft area) in untreated diabetic rats (DM) (e) was significantly larger than in the other three groups.
Although mesangial matrix was significantly greater in the DM group than in the ND and ND+EM groups, treatment with erythromycin significantly reduced mesangial expansion by 60.5% (f). Data are means±SEM values of six rats in each group. *p<0.0001 1 ng of [γ-
32 P] ATP 32 P-labelled oligonucleotide in 20 μl binding buffer (10 mmol/l Tris-HCl [pH 7.5], 50 mmol/l NaCl, 0.5 mmol/l EDTA, 0.5 mmol/l DTT, 1 mmol/l MgCl 2 , 4% glycerol and 50 mg/ml poly dI-dC) for 20 min at room temperature. Individual samples were then electrophoresed on a 4% polyacrylamide gel. After electrophoresis, the gel was dried and exposed to an imaging plate (Fujifilm, Tokyo, Japan). The autoradiogram was read by a FUJIX BAS-2000 (Fujifilm) and the relative intensity of the autoradiogram was determined using image analysis software (Scion). To assess the specificity of the reaction, a competition assay was performed in which 100-fold excess unlabelled NF-κB consensus sequences were added to the binding reaction 20 min prior to the radiolabelled NF-κB oligonucleotide. Each experiment was performed three times. For supershift/antibody competition assay, antibody against the p65 subunit (Active Motif, Tokyo, Japan) was incubated with nuclear extract for 20 min at 4°C before the binding reaction.
Antibodies
The primary antibodies used were mouse anti-rat monocyte/macrophage (ED1) monoclonal antibody (Serotec, Oxford, UK), purified mouse anti-rat ICAM-1 (CD54) monoclonal antibody (Seikagaku, Tokyo, Japan) and rabbit anti-mouse type IV collagen antibody (LSL, Tokyo, Japan).
The secondary antibodies were biotin-labelled goat antimouse IgG (Jackson Immunoresearch Laboratories, West Grove, PA, USA), fluorescein-isothiocyanate-conjugated goat anti-mouse IgG (Jackson Immunoresearch Laboratories) and fluorescein-isothiocyanate-conjugated goat antirabbit IgG (H+L) (Zymed laboratories, San Francisco, CA, USA).
Statistical analysis
All data are expressed as the mean±SEM. Differences between groups were examined for statistical significance using ANOVA followed by Scheffé's test. A p value of less than 0.05 denoted the presence of a statistically significant difference.
Results
Protocol 1
Time course of metabolic data and functional measurements
Changes in metabolic data and functional measurements are shown in Table 1 . There was no significant difference in HbA 1 c, or body weight between the DM and DM+EM Fig. 3 ICAM-1 production (a-d) and macrophage infiltration (e-h). Kidney tissues were taken from non-diabetic rats (a, e), non-diabetic rats treated with erythromycin (b, f), untreated diabetic rats (c, g) and erythromycin-treated diabetic rats (d, h). The production of ICAM-1 protein and infiltration of ED-1-positive cells (macrophage: arrows) into glomeruli were predominantly observed in glomeruli from untreated diabetic rats and were significantly inhibited in erythromycin-treated diabetic rats (magnification ×400). Immunofluorescence intensity for ICAM-1 (ICAM-1 index) (i) and the number (j) of ED-1-positive cells (macrophages). Data are means±SEM values of six rats in each group. *p<0.0001; **p<0.01; †p<0.05 groups. While relative kidney weights in the DM and DM+ EM groups were significantly higher than in the ND and ND+EM groups, there was no significant difference between the DM and DM+EM groups. There were no significant differences in systolic blood pressure, serum creatinine and Ccr among the four groups at weeks 4 and 8.
Urinary albumin excretion
Urinary albumin excretion after induction of diabetes is shown in Fig. 1 . Urinary albumin excretion in untreated diabetic rats (DM group) progressively increased at weeks 4 and 8 compared with non-diabetic rats (ND group) and nondiabetic rats treated with erythromycin (ND+EM group). However, the treatment with erythromycin significantly reduced urinary albumin excretion by 59.5% at week 8 (p<0.01).
Kidney morphology
Periodic acid-methenamine staining in glomeruli from each group is shown in Fig. 2a-d . Glomerular hypertrophy and mesangial matrix expansion were evaluated by calculating glomerular size (tuft area) and mesangial matrix index. The tuft area was significantly larger in the DM group than in the other three groups (p<0.0001) (ND vs ND+ EM vs DM vs DM+EM: 7605±156 vs 7340±136 vs 8784± 175 vs 7460±145 μm 2 ; Fig. 2e ). Although the mesangial matrix was significantly greater in the DM group than in the ND and ND+EM groups, erythromycin treatment significantly reduced mesangial expansion by 60.5% (Fig. 2f) .
ICAM-1 production and macrophage infiltration into glomeruli
Immunofluorescence staining for ICAM-1 in glomeruli and immunoperoxidase staining for ED-1 (macrophages) is shown in Fig. 3a -h. The ICAM-1 index was calculated to quantify ICAM-1 immunofluorescence intensity. The production of ICAM-1 protein in the DM group showed a nearly five-fold increase compared with the ND and ND+ EM groups and exhibited a 64% reduction by the treatment with erythromycin (Fig. 3i) . The number of ED-1-positive cells (macrophages) in glomeruli was significantly higher in untreated diabetic rats than in non-diabetic rats and nondiabetic rats treated with erythromycin. The infiltration of macrophages was significantly suppressed by treatment with erythromycin (ND vs ND+EM vs DM vs DM+EM: 0.2±0.03 vs 0.3±0.04 vs 1.6±0.08 vs 0.9±0.07 cells/ glomerulus; Fig. 3j ). 5 Quantitative analysis of type IV collagen in glomeruli from non-diabetic rats (a), untreated diabetic rats (b) and diabetic rats treated with erythromycin (c). The immunofluorescence intensity of type IV collagen was estimated using the same method as for the ICAM-1 index (d). The intensity of type IV collagen in glomeruli was significantly higher in the DM group than in the ND group, the increase in type IV collagen production was markedly inhibited by treatment with erythromycin (DM+EM). Data are mean±SEM values of six rats in each group. *p<0.0001; **p<0.005
Expression of Tgfb1 mRNA and type IV collagen protein in renal tissue
To investigate the inhibitory effect of erythromycin on Tgfb1 mRNA expression in renal cortex, quantitative realtime RT-PCR was performed. The level of Tgfb1 mRNA was normalised to the level of Actb mRNA in each sample by calculating the relative expression ratio. Tgfb1 mRNA expression in untreated diabetic rats was 1.6-fold higher than in non-diabetic rats (p<0.01). Erythromycin treatment reduced the increase of Tgfb1 mRNA expression by 83.5%, p<0.05 vs DM group) (Fig. 4) . Melting curve analysis confirmed the specificity of the Tgfb1 and Actb PCR products (data not shown).
Immunofluorescence staining for type IV collagen in glomeruli is shown in Fig. 5a -c. To quantify the intensity of type IV collagen expression, the immunofluorescence intensity was calculated using the same method as for the ICAM-1 index. The intensity of type IV collagen in glomeruli was significantly higher in the DM group than in the ND group; the intensity in the DM+EM group was markedly lower than in the DM group (Fig. 5d) .
NF-κB activation
The activation of NF-κB DNA binding activity, which is involved in gene expression for a variety of inflammatory mediators and adhesion molecules, was analysed by electrophoretic mobility shift assay (Fig. 6a) . NF-κB DNA binding activity is shown as intensity relative to background level (lane 6). NF-κB activation was 1.3-fold higher in the kidneys of untreated diabetic rats than in non-diabetic rats and was significantly reduced by treatment with erythromycin (Fig. 6b) .
Activation of p65 subunit
Supershift/antibody competition assays were performed to evaluate the specificity of the NF-κB components. Supershift assays demonstrated that an antibody directed against the p65 subunit supershifted NF-κB binding (Fig. 7) .
Ccl2 gene expression in renal tissue
The expression of Ccl2, known to be NF-κB-dependent and one of the major mediators of macrophage recruitment, Fig. 6 Electrophoretic mobility shift assay for NF-κB (a). ND, non-diabetic rats; DM, untreated diabetic rats; DM+EM, erythromycin-treated diabetic rats. Lanes 1-3, NF-κB activation. Lanes 4 and 5, specificity of NF-κB DNA binding. Lane 4, without nuclear extract; lane 5, pretreated with excess cold mutant NF-κB. Lane 6, pretreated with excess cold NF-ĸB. b Results of densitometric analysis of NF-κB activation in the kidneys. Data are expressed as mean±SEM values of six rats in each group. *p<0.01, **p<0.005 Fig. 7 The specificity of the NF-κB components evaluated by supershift/antibody competition assay. Lane 1, nuclear extracts from the DM+EM group; lane 2, nuclear extracts from the DM group without antibody; lane 3, an antibody against the p65 subunit was added with the nuclear extracts from the DM group. The gel shown is representative of five separate experiments was evaluated by quantitative real-time RT-PCR. The renal expression of Ccl2 paralleled the changes in NF-κB and renal macrophage infiltration, but were not statistically significant (Fig. 8) . Melting curve analysis confirmed the specificity of the Ccl2 PCR products (data not shown).
Protocol 2
To assess glomerular haemodynamic changes in earlier stage of diabetes in this experimental model, an additional experiment was performed 2 weeks after induction of diabetes. Metabolic data and functional measurements are shown in Table 2 . At 2 weeks after induction of diabetes, Ccr was significantly higher in the DM and DM+EM groups than in the ND and ND+EM groups. However, the level of Ccr was not significantly different between the DM and DM+EM groups. Relative kidney weights in the DM and DM+EM groups were significantly higher than in the ND and ND+EM groups, although there were no significant differences between the DM and DM+EM groups.
There were no significant differences in systolic blood pressure and serum creatinine among the four groups and the HbA 1 c level was not significantly different between the DM and DM+EM groups.
Discussion
The major findings of the present study were that continuous erythromycin treatment prevented renal injuries and macrophage infiltration into renal tissue through suppression of ICAM-1 production without change of blood glucose level and blood pressure in experimental diabetic rats. The renoprotective effect of erythromycin may result from its anti-inflammatory effect via inactivation of NF-κB, which is one of the major transcription factors for ICAM-1, proinflammatory cytokines [21] and chemokines [22] [23] [24] . Supershift assays suggested that the activation of p65 subunit contributes to the pathogenesis of the inflammatory mechanisms in diabetic nephropathy.
Lee et al. [24] reported that the active subunit of NF-κB, p65, was elevated in the kidney of diabetic rats and associated with Ccl2 expression and macrophage infiltration. Our results are consistent with their report. Although we did not detect the significant change in renal Ccl2 expression in the ND, DM and DM+EM groups, Ccl2, which is NF-κB-dependent, might also contribute to the inflammatory processes in diabetic kidneys.
ACEI and ARB are known to play central roles in the treatment of diabetic nephropathy, mainly by improving glomerular haemodynamic abnormalities. Recently, it was reported that angiotensin II induces cytokine/chemokine production and NF-κB activation in the kidney, and that ACEI and ARB, which are known to reduce TGFB upregulation, ameliorate a series of inflammatory process [22, [25] [26] [27] . It has also been reported that the renoprotective effects of ARB are related to inhibition of the NF-κB-dependent pathway in modulating macrophage infiltration in diabetic nephropathy [24] . Thus, the effects of ACEI and ARB on diabetic nephropathy may at least partly be related to anti-inflammatory actions.
We have previously demonstrated that ICAM-1 is expressed on glomerular endothelial cells and peritubular capillaries and promotes the infiltration of macrophages into kidney in diabetic patients and animal models of diabetes [10] [11] [12] . Furthermore, we induced diabetes in ICAM-1 knock-out mice and examined the change of renal injuries. ICAM-1 deficiency resulted in suppression of macrophage infiltration into renal tissue, as well as of TGFB and type IV collagen production and urinary albumin excretion, as compared with diabetic wild-type mice [13] . Some other reports show the correlation between diabetes and inflammatory phenomena in the kidney. High glucose activates the TGFB-dependent Smad signalling pathway to stimulate collagen synthesis in diabetic kidney [28] . Gruden and co-workers [29] reported that mechanical stretch induces CCL2 production via the NF-κB-dependent pathway in human mesangial cells. Mezzano et al. [30] reported that the activation of NF-κB and chemokines such as CCL2 and RANTES (regulated upon activation, normal T expressed and secreted) was strongly upregulated in renal tissues of human diabetic nephropathy. Moreover, high glucose upregulates peroxisome proliferator-activated receptor-γ (PPAR-γ), and PPAR-γ agonists exert antifibrotic, anti-proliferative and anti-inflammatory effects in renal proximal tubular cells under high glucose conditions by attenuating the increase in activator protein-1, TGFB1 and the downstream production of the extracellular matrix protein [31, 32] . These data also suggest that inflammatory mechanisms are involved in the progression of diabetic nephropathy.
On the other hand, mechanical stretch and high glucose directly stimulate Tgfb1 expression and TGFB1 production in cultured mesangial cells, resulting in collagen accumulation [33] [34] [35] [36] . These results indicate that metabolic and haemodynamic changes may also induce extracellular matrix accumulation independently of inflammation in the development of diabetic glomerulosclerosis.
We have recently shown that statin treatment downregulates ICAM-1 expression by inhibiting NF-κB activation, and protects from renal damage in experimental diabetic rats [20] . Utimura and co-workers [37] have also reported that mycophenolate mofetil attenuated renal damage in streptozotocin-induced diabetic rats by its antiinflammatory effects. These data suggest that inflammatory mechanisms might be a new target in the therapy of diabetic nephropathy.
Recently, another study using mice with bleomycininduced lung injury [18] showed that macrolides inhibited the expression of mRNA transcripts of the genes for vascular adhesion molecule-1 and ICAM-1 in lung tissues and attenuated the migration of inflammatory cells, especially neutrophils and macrophages, into air spaces. With respect to the direct effect on vascular endothelial cells, Enomoto et al. [38] reported that erythromycin directly reduced ICAM-1 expression that was upregulated by TNF-α stimulation using cultured vascular endothelial cells. These data support the results of the present study. On the other hand, it was reported that macrolides directly act on monocytes or macrophages and inhibit the production of inflammatory cytokines such as IL-1, IL-8 and TNF-α in vitro [39, 40] . It was also reported that macrolides, including erythromycin, inhibit NF-κB activation in mononuclear cells and macrophages [41] [42] [43] . Kikuchi and colleagues [44] reported that clarithromycin suppressed lipopolysaccharide-induced IL-8 production in human peripheral monocytes and in the human monocytic leukaemia cell line THP-1, through suppression of activator protein-1, and NF-κB transcription factors. These in vitro findings suggest that in our study, erythromycin might have directly acted on macrophages as well as on glomerular endothelial cells.
In our study, erythromycin treatment prevented glomerular hypertrophy in diabetic rats. The treatment with erythromycin did not change elevated Ccr in diabetic rats at 2 weeks after induction of diabetes, indicating that erythromycin does not affect glomerular haemodynamic changes. Therefore, we suggest that erythromycin does not reduce glomerular size by modulating haemodynamics, but rather by suppressing mesangial cell hypertrophy and extracellular matrix expansion, which is mainly composed of type IV collagens. It has previously [45] been shown that the early characteristic features of diabetic nephropathy, including glomerular hypertrophy and increased matrix synthesis, are largely mediated by increased TGFB activity in the kidney. The present study suggests that erythromycin treatment reduces the increase of type IV collagens and mesangial matrix expansion by modulating the inflammatory processes and through that suppressing TGFB activity.
In conclusion, in our present study erythromycin reduced ICAM-1 production and macrophage infiltration through suppression of NF-κB activation. The mechanism is partly similar to that in chronic obstructive pulmonary disease, diffuse panbronchiolitis and sinusitis. Low-dose and long-term administration of erythromycin is in common clinical use, and the safety of the therapy is established. Thus, modulation of inflammation with erythromycin might provide a new approach for diabetic nephropathy.
